Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters

References

• Adeyinka A, Emberley E, Niu Y, Snell L, Murphy LC, Sowter H, Wykoff CC, Harris AL, Watson PH. (2002). Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res 8:3788–3795.
   PubMed Web of Science ®Google Scholar
• Anand BS, Katragadda S, Nashed YE, Mitra AK. (2004). Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Curr Eye Res 29:153–166.
   PubMed Web of Science ®Google Scholar
• Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M. (1995). Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380–1385.
   PubMed Web of Science ®Google Scholar
• Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ. (1998). Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250:246–251.
   PubMed Web of Science ®Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, Matter A. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493–502.
   PubMed Web of Science ®Google Scholar
• Chan HS, Thorner PS, Haddad G, Ling V. (1990). Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689–704.
   PubMed Web of Science ®Google Scholar
• Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614.
   PubMed Web of Science ®Google Scholar
• de Miranda P, Blum MR. (1983). Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 12 Suppl B:29–37.
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640–2653.
   PubMed Web of Science ®Google Scholar
• Fuchs BC, Bode BP. (2005). Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254–266.
   PubMed Web of Science ®Google Scholar
• Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. (1998). Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 246:470–475.
   PubMed Web of Science ®Google Scholar
• Laco GS, Collins JR, Luke BT, Kroth H, Sayer JM, Jerina DM, Pommier Y. (2002). Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry 41:1428–1435.
   PubMed Web of Science ®Google Scholar
• Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R. (1993). Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81:2394–2398.
   PubMed Web of Science ®Google Scholar
• Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ. (1999). Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 289:448–454.
   PubMed Web of Science ®Google Scholar
• Gupta N, Prasad PD, Ghamande S, Moore-Martin P, Herdman AV, Martindale RG, Podolsky R, Mager S, Ganapathy ME, Ganapathy V. (2006). Up-regulation of the amino acid transporter ATB0,+ (SLC6A14) in carcinoma of the cervix. Gynecol Oncol 100:8–13.
   Google Scholar
• Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadée W, Amidon GL. (1998). 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 15:1154–1159.
   PubMed Web of Science ®Google Scholar
• Han HK, Oh DM, Amidon GL. (1998). Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res 15:1382–1386.
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Haramura M, Fei YJ, Miyauchi S, Bridges CC, Ganapathy PS, Smith SB, Ganapathy V, Ganapathy ME. (2004). Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308:1138–1147.
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. (1999). Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532–2535.
   PubMed Web of Science ®Google Scholar
• Hyde R, Taylor PM, Hundal HS. (2003). Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochem J 373:1–18.
   PubMed Web of Science ®Google Scholar
• Jung D, Dorr A. (1999). Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 39:800–804.
   PubMed Web of Science ®Google Scholar
• Katragadda S, Jain R, Kwatra D, Hariharan S, Mitra AK. (2008). Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. Int J Pharm 362:93–101.
   PubMed Web of Science ®Google Scholar
• Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–3547.
   PubMed Web of Science ®Google Scholar
• Landowski CP, Song X, Lorenzi PL, Hilfinger JM, Amidon GL. (2005). Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res 22:1510–1518.
   PubMed Web of Science ®Google Scholar
• Landowski CP, Vig BS, Song X, Amidon GL. (2005). Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther 4:659–667.
   PubMed Web of Science ®Google Scholar
• Lerchen HG. (1999). Camptothecin antitumor agents. IDrugs 2:896–906.
   Google Scholar
• Li F, Hong L, Mau CI, Chan R, Hendricks T, Dvorak C, Yee C, Harris J, Alfredson T. (2006). Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J Pharm Sci 95:1318–1325.
   PubMed Web of Science ®Google Scholar
• Li F, Maag H, Alfredson T. (2008). Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 97:1109–1134.
   PubMed Web of Science ®Google Scholar
• Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. (2000). The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 (Pt 11):2011–2021.
   Google Scholar
• Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, Repka MA. (2009). Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm Res 26:1261–1269.
   PubMed Web of Science ®Google Scholar
• Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. (1999). Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559–4563.
   PubMed Web of Science ®Google Scholar
• Nooter K, de la Riviere GB, Klijn J, Stoter G, Foekens J. (1997a). Multidrug resistance protein in recurrent breast cancer. Lancet 349:1885–1886.
   PubMed Web of Science ®Google Scholar
• Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA. (1997b). The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76:486–493.
   PubMed Web of Science ®Google Scholar
• Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T. (1995). Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72:550–554.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O’Grady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F. (2000). Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44:2811–2815.
   PubMed Web of Science ®Google Scholar
• Potmesil M, Pinedo HM. (1995). Camptothecins: new anticancer agents: CRC.
   Google Scholar
• Rozen S, Skaletsky H. (2000). Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365–386.
   PubMedGoogle Scholar
• Sawada K, Terada T, Saito H, Hashimoto Y, Inui KI. (1999). Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J Pharmacol Exp Ther 291:705–709.
   PubMed Web of Science ®Google Scholar
• Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. (2005). Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm 2:157–167.
   PubMed Web of Science ®Google Scholar
• Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39:2759–2764.
   PubMed Web of Science ®Google Scholar
• Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. (2000). Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 89:781–789.
   PubMed Web of Science ®Google Scholar
• Sun Y, Sun J, Shi S, Jing Y, Yin S, Chen Y, Li G, Xu Y, He Z. (2009). Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Mol Pharm 6:315–325.
   PubMed Web of Science ®Google Scholar
• Tsume Y, Hilfinger JM, Amidon GL. (2008a). Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm 5:717–727.
   PubMedGoogle Scholar
• Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, Amidon GL. (2008b). Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules 13:1441–1454.
   PubMed Web of Science ®Google Scholar
• Umapathy NS, Ganapathy V, Ganapathy ME. (2004). Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res 21:1303–1310.
   PubMed Web of Science ®Google Scholar
• Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL. (2003). Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 20:1381–1388.
   PubMed Web of Science ®Google Scholar
• Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H. (2001). Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514:291–302.
   PubMed Web of Science ®Google Scholar